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tion centers in Lagos was fully potent, but
potency in Osun and Oyo was 016 log10 to 0.22
log10 lower than the stipulated level (2).
Furthermore, the titer of two vaccine lots that
had been frozen after reconstitution from their
lyophilized state dropped from the initial 3.15
log10 to 3.53 log10 to zero.
If the United States were to implement an
extended strategy, similar studies of vaccine lots
should be conducted to determine whether every
vaccinee has received a full dose of yellow fever
vaccine. In Illinois during the early 1970s, weak
links in maintenance of refrigeration facilities
and use of outdated vaccines in vials exposed to
the sun for long hours were reported for live
poliovirus vaccines (3). In the Northern
Territory of Australia, examination of 144 vials
of hepatitis B vaccine formulations during
transport to immunization centers showed that
47.5% had been exposed to temperatures of -3°C
or lower (4).
Assays of the potency of yellow fever vaccine,
as well as quantification of vaccine-induced
neutralizing antibody, is a multistep procedure
that relies on inoculation of mice or Vero or
polysaccharide cells (5). The successful take of
yellow fever vaccine can be determined starting
the second postvaccination day by demonstrable
viremia detected by reverse-transcriptase poly-
merase chain reaction and by marked increases
in neopterin, beta2-microglobulin, and circulat-
ing CD8+ cells (6). Alternatively, elevated levels
of tumor necrosis factor and interleukin-1
receptor antagonists on day two after vaccina-
tion (7) could be used to monitor the success of
vaccinations by primary-care providers in
remote areas in the United States (1) and
elsewhere.
During the 1990s, isolation of yellow fever
virus was reported in persons with a nonspecific
febrile illness that did not meet the case
definition of yellow fever (8). Air travel by such
persons to the United States, which has areas
infested by Aedes aegypti, could initiate yellow
fever epidemics; because these travelers would
have a nonspecific febrile illness, they would
escape the existing surveillance network.
In conclusion, introducing yellow fever
immunizations by primary health-care providers
would be ideal, only with a concurrent plan to
monitor vaccine potency at immunization
centers and obtain in vitro evidence of a successful
vaccine take. Such a strategy would blunt yellow
feverassociated deaths, illnesses, and symp-
tomless viral carriage in the community.
Subhash C. Arya
Centre for Logistical Research and Innovation
New Delhi, India
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Yellow Fever Vaccine—Reply to S. Arya
To the Editor:  Dr. Arya correctly points out that
there have been problems with degradation of
live viral vaccines, including yellow fever
vaccines, that have not been properly handled
and stored at the point of use. However, in the
United States and western Europe, yellow fever
vaccines are stabilized and require the same
storage facilities at the point of use as other
vaccines routinely distributed by family physi-
cians and pediatricians. Varicella vaccine (and
even measles vaccine) is less stable than yellow
fever vaccine but is distributed to all registered
physicians in the United States. Since vaccines
and other perishable medicines are typically489 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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shipped by overnight courier services using
qualified methods that ensure maintenance of
low temperature, there is no barrier to use of a
similar system for yellow fever vaccine.
Empirical testing for antibody, viremia, or
even surrogate markers of T-cell activation may
be useful; however, it is difficult and expensive,
involves unvalidated tests with unknown
sensitivity and specificity, and is unnecessary,
except under very special circumstances. A more
direct measure of vaccine stability is direct
potency measurement of samples stored at the
point of use, as was done in the cited study in
Nigeria by Adu et al. However, given the current
controls on vaccine distribution in the United
States, we do not believe that there would be a
need to validate vaccine effectiveness at point of
use in the event of a change of policy with respect
to vaccinating centers. The cold-chain infra-
structure and the training of medical personnel
in vaccine storage and administration may not
provide the same assurances in other countries.
While our suggested changes to the system of
yellow fever distribution may improve vaccine
coverage and have other desirable benefits in the
United States, they would not be appropriate for
less stable systems for vaccine supply and use.
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